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Summary
Background Conflicting evidence exists concerning the protective role of breastfeeding in
allergy and atopic disease aetiology. Breast milk contains biologically active molecules
influencing the innate immune system of newborns.
Objective We aim to assess whether cytokines (TGF-b1, IL-10 and IL-12) and soluble CD14
(sCD14) in breast milk are influenced by maternal atopic constitution and modify the
development of atopic manifestations in infants.
Methods Milk samples were collected at 1 month post-partum of 315 lactating mothers
participating in the ongoing KOALA Birth Cohort Study. The cytokines and sCD14 were
analysed by ELISA in the aqueous fraction. We compared the concentrations of cytokines and
sCD14 in breast milk between mothers with and without an allergic history and also with and
without allergic sensitization (specific IgE). Associations of cytokines and sCD14 with the
development of eczema, wheezing in the first 2 years of life and allergic sensitization of
infants at the age of 2 years were analysed by multivariate logistic regression analyses to
correct for confounders.
Results We found higher sCD14 levels in mothers with a positive vs. negative allergic history
(7.6 vs. 7.0 mg/mL; P= 0.04) and in mothers who were sensitized vs. non-sensitized (7.8 vs. 7.1
mg/mL; P= 0.03). None of the studied immune factors were associated with infant’s atopic
outcomes. IL-10 was not detected above the detection limit of 0.2 pg/mL.
Conclusion Taking together the results of the present and previous studies, we conclude that
there is no convincing evidence for a relation between TGF-b1, sCD14, IL-10 or IL-12 in breast
milk and atopic manifestations in infants.
Keywords cytokines, eczema, human milk, immunoglobulin E, soluble CD14
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Introduction
Atopic diseases such as atopic eczema, allergic rhinitis
and allergic asthma have increased in the developed world
during recent decades [1]. Breastfeeding has been consid-
ered to afford protection against atopic disorders. Protec-
tion may be conveyed by biologically active molecules
that are present in human milk such as cytokines, chemo-
kines, hormones, growth factors, secretory antibodies and
essential fatty acids [2, 3]. Through several mechanisms,
immune-modulating factors in human milk can actively
stimulate the newborn’s immune system, which is rapidly
maturing during the first years of life [4]. In the current
study, we focus on four immune factors [TGF-b1, IL-10,
IL-12 and soluble CD14 (sCD14)] that may influence the
innate immune system.
TGF-b1 and IL-10 are anti-inflammatory cytokines
produced by several cell types, including regulatory
T cells, which are currently in the focus of allergy and
asthma research [5]. Regulatory T cells suppress both
T-helper type-1 (Th1)- and Th2-mediated immune re-
sponses [6] and are thought to play a role in the develop-
ment of allergic disease [7]. Especially, TGF-b1 is an
abundant cytokine in human milk [8]. Oddy et al. [9]
demonstrated a positive association between low concen-
trations of TGF-b1 in human milk and infant wheezing.
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Human milk also contains IL-12 and the soluble form
of CD14 (sCD14). Both are lipopolysaccharide (LPS)
[10]-associated immune factors that promote Th1 devel-
opment, thereby preventing excessive IgE production and
allergic inflammation [11]. CD14 is an innate immune
receptor for LPS, a component of gram-negative bacterial
cell walls [12]. The complex interplay between CD14,
toll-like receptor (TLR) 4 and MD-2 is responsible
for recognition of LPS [13]. Subsequently, intracellular
signalling results in secretion of IL-12. An association was
found between reduced sCD14 levels in breast milk and a
diagnosis of eczema in children aged 6 months [14].
Recently, increased levels of sCD14 were found to be
associated with a lower incidence of doctor’s diagnosed
asthma at the age of 2 years, especially in children of
mothers without a history of atopic diseases [15]. Also, a
deficit of IL-12 production was proposed to occur in
atopic individuals [11].
There are two possible explanations for the relation
between levels of immune factors in breast milk and the
development of atopy in the infant: first, maternal atopic
constitution (genetic or acquired) determines levels of
cytokines in breast milk and infant’s atopy by separate
mechanisms; second, immune factors have a direct effect
on mucosal immunity in the child.
This study had two objectives. First, we aimed to
investigate whether the mother’s atopic constitution
influences milk levels of TGF-b1, IL-10, IL-12 and sCD14.
Second, we examined whether these immune factors
are associated with the development of infant’s atopy
(eczema, wheezing) in the first 2 years of life and allergic
sensitization at age 2.
Methods
Design
This study is part of the KOALA Birth Cohort Study
(N= 2834), an ongoing prospective birth cohort study in
the Netherlands. The design of the study has been de-
scribed, in detail, elsewhere [16]. Briefly, we recruited
participants with diverse lifestyles (conventional and
alternative) at 34 weeks of gestation. Pregnant women
with a conventional lifestyle (n= 2343) were recruited
from an ongoing prospective cohort study on pregnancy-
related pelvic girdle pain in the Netherlands. Additionally,
pregnant women with an alternative lifestyle (n= 491)
were recruited through several ‘alternative’ channels:
organic food shops, anthroposophic doctors and mid-
wifes, Steiner Schools and magazines. During the first
2 years post-partum, information on breastfeeding, atopic
outcomes and their determinants was collected for all
members of the cohort by repeated questionnaires at 3, 7,
12 and 24 months. During home visits at 34–36 weeks of
gestation, maternal venous blood was collected. From
October 2002, we started recruiting participants for breast
milk sampling by asking pregnant mothers who intended
to start breastfeeding to consent for breast milk collection.
This resulted in breast milk being sampled in 315 breast-
feeding mothers between December 2002 and September
2003, including a short questionnaire at the time of breast
milk collection (1 month post-partum). The study (includ-
ing biosampling) was approved by the medical ethics
committee of the Maastricht University.
Collection and processing of breast milk
Mothers received a sterile 50mL tube (Cellstar PP-test
tubes, Greiner bio-one, Kremsmu¨nster, Austria) and were
instructed to collect the milk sample in the morning,
before breastfeeding their child, from the contra-lateral
breast (since the last feeding) and to keep the tube in the
refrigerator ( 4 1C) until it was collected by one of the
researchers. If the mother was not able to collect the milk
sample by herself (with or without a pumping regimen),
an electric breast pump (Medela, Baar, Switzerland) was
used with the help of one of the researchers (within the
same day). During transport, the milk samples were stored
in a cooler (Coleman Company Inc., Breda, the Nether-
lands) on packed ice ( 4 1C) until processing on the same
day. The sample was centrifuged (400 g, 12min, no brake,
4 1C) to separate the lipid and aqueous fraction. The lipid
layer was trimmed off with a pipette and released in
plastic storage vials (Sarstedt, Nu¨mbrecht, Germany). The
aqueous fraction was poured in other vials with another
pipette. The remaining debris was not used to avoid
contamination with cell fragments. All fractions were
stored at –80 1C in the European Biobank, Maastricht.
Enzyme linked immunosorbent assays in breast milk
Quantitative colorimetric cytokine ELISA kits were used to
assess the concentrations of TGF-b1, sCD14 (R&D Systems
Europe Ltd., Abingdon, UK), IL-10 and IL-12 (Biosource
Int., Camarillo, CA, USA) in human aqueous milk fractions
according to the manufacturer’s instructions. The aqueous
milk fractions were assayed at dilution factors of 1.4 for
TGF-b1 and 2000 for sCD14. The minimum detectable
dose of TGF-b1 and sCD14 was 7 pg/mL and 125 pg/mL,
respectively. For the activation of latent TGF-b1 to the
active form, a standard activation procedure was used.
Briefly, 0.1mL 1M HCl was added to 0.5mL aqueous milk
fraction and subsequently mixed to incubate for 10min at
room temperature. Neutralization of the acidified milk
sample was performed by adding 0.1mL 1.2 M NaOH/0.5 M
4-(2-hydroxyethyl)-1-piperazine-ethanesulfonic acid. Un-
diluted aqueous milk fractions were used to determine the
IL-10 and IL-12 concentrations. The minimum detectable
dose was 0.2 pg/mL for IL-10 and 0.8 pg/mL for IL-12. All
ELISA assays were performed in duplicate. We conducted
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a pilot study for all parameters. We could not detect IL-10
concentrations in our pilot study (n= 16).
Determination of maternal and infant’s total and specific
Immunoglobulin E
Maternal venous blood samples were obtained during a
home visit at 34–36 weeks of gestation. Serum samples
were analysed for total IgE levels as described earlier [17,
18]. For values o 150 IU/mL a sandwich RIA was used
[17], and for values 4 150 IU/mL a competitive RIA was
used [18]. Maternal venous blood samples were analysed
for specific IgE against 13 common respiratory and food
allergens. Calculation was performed by means of a
standard curve that was obtained by RAST with a dilution
series of a chimeric monoclonal IgE antibody against the
major allergen Der p 2 and Sepharose-coupled recombi-
nant Der p 2 [19].
In order to collect venous blood of the infants, home
visits were made at 2 years post-partum. Infants’ venous
blood samples were analysed for specific IgE against hen’s
eggs, cow’s milk, peanuts, birch, grass pollen, cat, dog and
mite using RAST as described earlier [18]. The detection
limit for total and specific IgE was 0.50 and 0.10 IU/mL,
respectively.
Definition of maternal allergic history and maternal
sensitization
A positive maternal allergic history was defined if, in her
self-reported questionnaire, the mother positively con-
firmed that a physician had at least once diagnosed
asthma, eczema, allergy for house dust mite/pets or
allergic rhinoconjunctivitis (such as hayfever).
Maternal sensitization was considered as present if
serum-specific IgE against one or more of the tested
inhalant or food allergens was positive (4 0.3 IU/mL).
High total IgE for mothers was arbitrarily defined as total
IgE level 4 100 IU/mL.
Definition of infant’s atopic manifestations and infant’s
allergic sensitization
Information on the development of eczema (based on
ISAAC questions) was obtained in the 3-, 7- and 12-
month questionnaires. Parents were asked; ‘has your child
ever had an itchy rash that was coming and going in the
past months’? If this question was answered affirmatively,
infants were defined as having developed eczema in the
first 2 years of life. Cases of only diaper rash, rash around
the eyes and/or scalp scaling were excluded. ‘Ever wheez-
ing’ was defined as parentally reported presence of
wheezing, with at least one attack, in the 7-, 12- or 24-
month post-partum questionnaires. Infants were consid-
ered to be sensitized if specific serum IgE-levels were
4 0.3 IU/mL against one or more of the tested food or
inhalant allergens. High total IgE for infants was arbitra-
rily defined as total IgE level 4 10 IU/mL.
Atopic dermatitis by UK Working Party criteria
To specify eczema reported by parents as described above,
we defined atopic dermatitis according to UK Working
Party criteria [20] for all infants who were visited at home
at age 2 years. The probability of the presence of atopic
dermatitis was derived from the presence of four clinical
symptoms: (1) presence of itchy rash (PIR, coded as
0 = absent, 1 = present), (2) history of flexural dermatitis
(HFD, 0 = absent, 1 = present), (3) visible flexural dermati-
tis (VFD, 0 = absent, 1 = present) and (4) onset before age
of 2 years (OB2, 0 = absent, 1 = present). The UK working
party (UK-WP) probability score of atopic dermatitis (AD)
is then computed as: probability AD= odds (AD)/[odds
(AD)11], where odds (AD) = exp[ 4.3611.84(HFD)1
3.46(OB2)12.09 (VFD) 11.71(PIR)] [20]. In this study,
infants with a UK-WP probability score of atopic derma-
titis (AD) 4 0.9 were regarded as infants with ‘probable
presence of atopic dermatitis’.
Statistical analysis
Extreme values of concentrations of cytokines and sCD14
were not excluded as these did not influence our results.
The mean values of concentrations of cytokines and
sCD14 were compared between groups using analysis of
variance (ANOVA). To assess the association between cyto-
kines and infant’s atopic manifestations, we conducted a
multivariate logistic regression analysis in order to adjust
for possible confounders (‘recruitment group’ (conven-
tional vs. alternative), maternal age (years), maternal
allergic history (yes/no), number of older siblings (no
siblings, one, two or more), season of breast milk collec-
tion (winter 2002–2003, spring 2003, summer 2003), use
of probiotics in capsules or yoghurts at 1 month post-
partum (yes/no), maternal infection in week of breast milk
collection (yes; that is, vomiting, diarrhoea, having a cold,
sore throat, mastitis, fever or urinary tract infection),
time-interval between birth and breast milk collection (in
days) and total storage time in freezer until analysis (in
days)). Based on sample sizes of previous studies [9, 14],
we estimated that 300 breast milk samples were sufficient
to detect differences of interest. We consider P-values
40.05 as statistically significant. All analyses are pre-
sented for both recruitment groups (conventional and
alternative cohort) together, because stratified analyses
showed similar results for both groups.
Results
A total of 315 mothers donated a breast milk sample at 1
month post-partum. This subcohort consisted of 60% of
c 2006 Maastricht University
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breastfeeding mothers from the KOALA study who were
visited for venous blood collection at 34–36 weeks of
gestation (from October 2002 onwards). The main reasons
for not donating breast milk were unsuccessful breast-
feeding or logistic reasons. The characteristics of these
mothers and their infants are summarized in Table 1.
We could determine TGF-b1 and sCD14 in 307 (98%)
breast milk samples, whereas IL-12 was determined in
293 (93%) samples. No data of IL-10 in breast milk are
presented as we did not detect IL-10 above the detection
limit of 0.2 pg/mL.
We found no difference in the mean concentrations of
TGF-b1 in breast milk between mothers with or without
an allergic history (Table 2). Also, the mean concentra-
tions of TGF-b1 in breast milk were not different between
mothers with and without allergic sensitization (P= 0.15;
Table 2) or between mothers with or without high levels of
total IgE (not shown). For sCD14, we found a somewhat
higher concentration in breast milk in mothers with an
allergic history compared with mothers without (7.6 vs.
7.0 mg/mL; P= 0.04) (Table 2). Also, we found a higher
concentration of sCD14 in mothers who were sensitized
compared with non-sensitized mothers (7.8 vs. 7.1 mg/mL,
P = 0.03; Table 2). The levels of sCD14 were similar in
mothers with high vs. low total IgE levels (7.3 vs. 7.2 mg/
mL; P= 0.84; results not shown in table). Finally, we did
not detect differences in the mean concentrations of IL-12
in breast milk between mothers with and without an
allergic history or between sensitized and non-sensitized
mothers (Table 2), nor between mothers with and without
high levels of total IgE (not shown).
The results for the relationships between the concentra-
tions of breast milk immune factors (in tertiles) and the
infant’s atopic outcome are presented in Table 3. The risk
of infant’s eczema (by questionnaires) and wheeze was not
associated with breast milk levels of TGF-b1, sCD14 and
IL-12 (odds ratios show no trend over the tertiles, and 95%
confidence intervals include the value 1.0). Also, no
association was present between the presence of allergic
sensitization and TGF-b1, sCD14 and IL-12 (Table 3).
Neither did we find an association between high total
serum IgE (410 IU/mL) or atopic dermatitis by UK-WP
criteria and TGF-b1, sCD14 and IL-12 (results not shown).
Discussion
In the present study, we found higher levels of sCD14 in
mothers with a maternal allergic history and sensitization.
No such associations between TGF-b1 and IL-12 in breast
milk and maternal allergic status were found. None of the
studied immune factors (TGF-b1, sCD14 and IL-12) in
breast milk were associated with infant’s atopic outcomes.
Our first aim was to assess whether milk levels of TGF-
b1, IL-10, IL-12 and sCD14 reflect the mother’s allergic
history. A few studies have compared the concentrations
of immune factors in breast milk between atopic and non-
atopic mothers. In a small study, Rigotti et al. [21] found
that TGF-b1 was significantly less in the mature milk of
allergic mothers. In agreement with the present study,
Table 1. Characteristics of participants (with conventional versus alter-
native lifestyle) with breast milk sample (N=315)
Conventional Alternative
N= 146 N=169
Maternal age in years (mean SD) 32.4 3.3 34.0 4.2
Breastfeeding duration in months
(meanSD)
4.2 3.0 6.5 3.1
Sex of infant (no. of boys, percentage) 71 (48.6%) 83 (49.1%)
Infant’s atopic outcome, at age 2 years
Eczema by questionnaire (yes,
percentage)
42 (28.8%) 51 (30.2%)
Atopic dermatitis by UK-WP (yes,
percentage)
16 (11.0%) 15 (8.9%)
Wheeze (yes, percentage) 41 (28.1%) 42 (24.9%)
Both eczema1 wheeze (yes,
percentage)
11 (7.5%) 12 (7.1%)
Cytokines and sCD14 in breast milk
TGF-b1 in pg/mL (mean SD)
N= 307w
225.6 178.3 212.5 117.8
Range TGF-b1 in pg/mL 12.0–1536.8 2.0–647.9
IL-10 in pg/mL NDz NDz
sCD14 in mg/mL (meanSD)
N= 307w
7.7 2.9 7.1 2.2
Range sCD14 in mg/mL 1.7–23.8 2.3–20.1
IL-12 in pg/mL (meanSD) N= 293w 10.6 6.5 10.8 6.0
Range IL-12 in pg/mL 0.7–52.8 1.5–51.6
Exclusive and non-exclusive breastfeeding.
wMissing due to insufficient aqueous fraction available.
zNot detectable i.e. under the detection limit of 0.2 pg/mL.
Table 2.Mean concentrations of TGF-b1, sCD14 and IL-12 in breast milk
related to maternal allergic history and specific serum IgE
TGF-b1 (pg/mL) sCD14 (mg/mL) IL-12 (pg/mL)
n
Mean
(SD) n
Mean
(SD) n
Mean
(SD)
Maternal allergic history
No 125 221.1 (140.1) 124 7.0 (2.4) 120 10.3 (6.2)
Yes 182 216.9 (155.1) 183 7.6 (2.6) 173 11.0 (6.3)
Pw 0.81 0.04 0.35
Maternal sensitization
No sensitization 164 207.9 (127.3) 164 7.1 (2.8) 164 10.4 (5.2)
Sensitization 123 238.1 (180.2) 123 7.8 (2.4) 123 11.1 (7.4)
Pw 0.15 0.03 0.35
SD, standard deviation.
Specific IgE 4 0.3 IU/mL for any of the 13 measured food or inhalant
allergens (missing n=6).
wP value based on ANOVA.
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Bo¨ttcher et al. [22] reported no differences for TGF-b. In
agreement with our findings, a small study found no
associations between IL-12 in breast milk and a maternal
atopic status [23]. Our findings of higher levels of sCD14
in mothers with a maternal allergic history (P= 0.04) or
mothers with sensitization (P = 0.03) have not been re-
ported earlier. However, the results of a German study
presented a slightly higher prevalence of maternal atopic
history in the upper quartile of breast milk sCD14, directed
towards borderline statistical significance (P= 0.07) [15].
Savilahti et al. [24] found lower levels of sCD14 in the
colostrum of atopic vs. non-atopic mothers when the
definition of atopy was based on a single symptom but
when a more rigid definition was used, the difference
disappeared. For sCD14 levels in breast milk, our results
tend towards a relation with both a maternal allergic
history and maternal sensitization but not with high total
IgE in the mother. We speculate that disease activity (at
the moment of breast milk sampling) in atopic mothers
may be reflected in higher sCD14 levels. Higher levels of
serum sCD14 are seen in subjects with disease activity for
instance after exacerbation of asthma in children [25, 26].
However, we did not assess the asthmatic status or the
presence of rhinoconjuctivitis at the moment of breast
milk sampling. Alternatively, atopic vs. non-atopic
mothers could differ in genetic constitution, leading to
different sCD14 levels. Guerra et al. [27] found that sCD14
levels in milk differed significantly by CD14/ 1619 and
CD14/ 550 genotypes and haplotypes. The biologic
relevance for the infant of such small differences in
sCD14 concentrations between atopic and non-atopic
mothers can be argued.
Our second aim was to assess whether TGF-b1, IL-10,
IL-12 and sCD14 levels in breast milk were associated with
the development of infant’s atopic manifestations. We
consider infant’s eczema (by questionnaire, adapted from
ISAAC) and sensitization as separate outcome parameters
instead of atopic eczema because sensitized infants do not
necessarily show symptoms of eczema or vice versa [28].
Consequently, we use the term eczema instead of
atopic eczema. However, we use the term ‘atopic dermati-
tis’ for infants fulfilling the UK-WP criteria according to
the criteria of Williams et al. [20]. If we used more
stringent criteria for wheeze such as proposed by others
[29], the number of cases was too small for a multivariate
analysis.
We found no associations between TGF-b1, sCD14 and
IL-12 and infants’ atopic outcomes. The Infant Immune
Study (Tucson, Arizona) found a statistically significant
association between low levels of TGF-b1 and wheeze at
the age of 1 year [9]. Furthermore, the British study of
Jones et al. [14] found that low levels of breast milk sCD14
were associated with a diagnosis of eczema in 6-month-
old infants, irrespective of skin prick testing, in a high-risk
cohort. More recently, Rothenbacher et al. [15] found a
lower risk for atopic eczema for breastfed infants (X6
months, sCD14 in the highest quartile) vs. less than 3
months’ breastfeeding. They suggested that the beneficial
Table 3. Adjusted odds ratios for the presence of eczema and wheezing in the first 2 years of life and allergic sensitization at age 2 years, depending on
the concentrations of TGF-b1, sCD14 and IL-12 (in tertiles) in breast milk
Infant’s eczema (by questionnaires) Infant’s wheeze Infant’s sensitization
n aOR (95% CI)w n aOR (95% CI)w n aOR (95% CI)w
TGF-b1 (pg/mL)
Low (2.0166.9) 30 1.0 (reference) 24 1.0 (reference) 17 1.0 (reference)
Middle (166.9 248.4) 32 1.14 (0.59-2.10) 28 1.21 (0.61-2.93) 21 1.19 (0.52-2.74)
High (248.51536.8) 28 1.00 (0.53-1.91) 28 1.13 (0.57-2.23) 12 0.51 (0.21-1.24)
P for trend 1.00 (N=299) 0.73 (N= 299) 0.13 (N= 200)
sCD14 (mg/mL)
Low (1.7 6.3) 29 1.0 (reference) 25 1.0 (reference) 16 1.0 (reference)
Middle (6.4 8.0) 38 1.70 (0.90-3.23) 26 1.38 (0.69-2.77) 18 1.11 (0.49-2.54)
High (8.1 23.8) 26 1.00 (0.50-2.00) 32 1.85 (0.92-3.69) 17 1.06 (0.46-2.47)
P for trend 0.98 (N=307) 0.08 (N= 307) 0.89 (N= 207)
IL-12 (pg/mL)
Low (0.6 7.8) 24 1.0 (reference) 24 1.0 (reference) 18 1.0 (reference)
Middle (7.911.8) 35 1.60 (0.83-3.11) 29 1.35 (0.68-2.69) 13 0.77 (0.32-1.89)
High (11.9 52.8) 26 1.18 (0.59-2.38) 22 1.06 (0.51-2.21) 15 0.77 (0.33-1.83)
P for trend 0.61 (N= 285) 0.84 (N= 285) 0.54 (N= 190)
aOR, adjusted odds ratio.
Sensitization is defined as specific serum IgE-levels 4 0.3 IU/mL against one or more of the tested food or inhalant allergens.
wFrom logistic regression analysis, adjusting for: recruitment group (conventional versus alternative), maternal age, maternal allergic history, number of
older siblings, season of breast milk collection, maternal use of probiotics, maternal infection (during week of breast milk collection), time interval
between birth and breast milk collection (in days) and total storage time in freezer until analysis (in days).
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effects of breastfeeding are supported by high levels of
sCD14. By contrast, Laitinen et al. found that sCD14
tended to be higher in mature breast milk received by
infants with vs. without atopic eczema with a positive skin
prick test. Previous studies have investigated IL-10 [9, 22,
30–32], IL-12 [23, 33, 34] or TGF-b1 [8, 9, 22, 24, 32, 35,
36] concentrations in breast milk with inconsistent results
with respect to the mothers and/or infant’s atopic out-
comes. We speculate that three explanations may clarify
these inconsistencies. First, differences in methodologies
could be an explanation, e.g. the moment of breast milk
sampling. It can be anticipated that cytokine concentra-
tions are higher in colostrum than mature milk. This is not
supported by a study with longitudinal human milk
collection, reporting a slight change in the mean concen-
tration of both TGF-b1 and TGF-b2 during the first 12
weeks of lactation, including colostrum [36]. However,
this may not necessarily apply for sCD14 and IL-12.
Second, the effects caused by colostral factors may no
longer be valid at the infant’s age of 1 month because the
permeability of the gut is diminishing and the efficiency
of proteolysis is enhanced [37]. In addition, Blais et al. [38]
found that sCD14 in breast milk is more susceptible
to the infant’s pancreatin digestion vs. pepsin digestion
by in vitro experiments, suggesting decreased activity of
sCD14 in the LPS-rich environment of the distal bowel.
Third, the use of different ELISA kits may explain incon-
sistent results between studies [23]. It was noted in two
studies that the use of ELISA assays of R&D Systems did
not detect IL-12 in breast milk [33, 34]. We were also
unable to detect IL-12 in breast milk with that same
ELISA. However, using a high-sensitivity kit (Biosource
Int.), we detected IL-12 in our breast milk samples.
Previously, IL-12 was also found in breast milk samples
in a study using ELISA assays of Pharmingen (San Diego,
CA, USA) [23].
A limitation of our study was a restriction of complete
standardization of breast milk collection. Different modes
of pumping and individual variation in pumping techni-
ques could have led to variation of the measured immune
factors. The strength of this study was the number of
breast milk samples available as only a few studies
measured sCD14 or cytokines in a large amount of breast
milk samples.
In summary, we found higher concentrations of
sCD14 in breast milk in mothers with a positive allergic
history and mothers with allergic sensitization but
not for high total IgE. Taking together the results
of the present study and other studies, we conclude that
there may be no consistent effect on inter-individual
differences of TGF-b1, sCD14 and IL-12 in breast milk
and the infant’s atopic outcomes. Therefore, the search
for the modifying effects of factors present in breast
milk on the development of atopic manifestations should
continue.
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